Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 150 /hr

★★★★★

☆☆☆☆☆

Hire Dr. Rohan J.

United States

USD 150 /hr

Neuroscientist Focused on Translational Risk, Trial Reality & Decision-Making in CNS Therapeutics

Profile Summary

Dr. Rohan Jagirdar is a neuroscientist with over 10 years of experience in academic and translational research, primarily focusing on Alzheimer's disease, sleep biology, and CNS therapeutics. Since May 2025, he has been working as a Field Application Scientist at Transvista Biotechnology Ltd., a groundbreaking manufacturer of miniature 2-photon microscopy based in Beijing, China. In his current role, he serves as an application expert, providing customer training and resolving technical and application issues related to the products. Before this, he worked as an Instructor (Faculty Researcher) at Baylor College of Medicine from July 2019 to January 2025. Baylor College of Medicine is a prestigious medical school in Texas and is also recognized as a top-ranking research institution in the United States. His work there involved sleep mechanism research, biomarker interpretation, and translational assessments across preclinical stages of Alzheimer's disease. He has contributed to peer-reviewed publications, including those in Science Translational Medicine. Dr. Jagirdar routinely advises on the biological plausibility, translational feasibility, and clinical trial realism of neuroscience programs, helping non-scientific stakeholders understand where scientific risk is concentrated and how early assumptions may impact downstream clinical outcomes. What types of expert calls are you best suited for? Dr. Jagirdar is best suited for expert calls involving evaluation of neuroscience and CNS drug development programs, particularly where there is uncertainty around translational relevance, biomarker strategy, or clinical trial design. This includes diligence calls for investors, strategy teams, and consultants seeking to understand whether a program's biology is sound, whether preclinical data meaningfully inform human disease, and whether proposed clinical endpoints and trial designs are realistic. What topics can you speak to in detail? Alzheimer's disease mechanisms and therapeutic strategies Translational challenges in neurodegenerative drug development Sleep and circadian biology as biomarkers or therapeutic targets Animal-to-human translation risks in CNS programs CNS clinical trial design, endpoints, and common failure modes Interpretation of early clinical signals (Phase 1/2) Competitive scientific landscape analysis in neuroscience What value do clients typically gain from speaking with you? Clients typically gain clarity around scientific and translational risk that is not obvious from published summaries or company materials. He helps identify key assumptions underlying a program, highlight where data are being over- or under-interpreted, and outline the practical implications for clinical development and decision-making. His goal is not to advocate for or against a program, but to help clients distinguish robust signal from biological or design-related noise. Are there topics you cannot discuss? Dr. Jagirdar does not discuss confidential or proprietary information from his current or prior roles, nor does he provide investment advice. His input is limited to publicly available information, general scientific principles, and professional judgment based on my experience.

Subject Matter Expertise

• ★ Neuroscience
• ☆ Molecular Neuroscience
• ☆ Neurobiology

Services

• Writing
• Research
• Consulting

Writing Technical Writing

Research Scientific and Technical Research

Consulting Scientific and Technical Consulting

Work Experience

Field application scientist

TRANSVISTA Biotechnology Ltd

May 2025 - Present

Instructor

Baylor College of Medicine

July 2019 - Present

Postdoctoral Associate

Baylor College of Medicine

July 2016 - June 2019

Research Assistant II

Baylor College of Medicine

November 2015 - June 2016

Education

Ph.D. Neuroscience

Medizinische Universität Innsbruck - Austria

January 2012 - October 2015

MSc Neuroscience

Rheinische Friedrich-Wilhelms-Universität Bonn

October 2009 - November 2011

BSc Biotechnology

University of Pune

May 2006 - May 2008

Certifications

• Certification details not provided.

Publications

JOURNAL ARTICLE

Rohan Jagirdar, Chia-Hsuan Fu, Jin Park, Brian F. Corbett, Frederik M. Seibt, Michael Beierlein, Jeannie Chin (2021). Restoring activity in the thalamic reticular nucleus improves sleep architecture and reduces Aβ accumulation in mice . Science Translational Medicine.

Jagirdar, Rohan, Fu, Chia-Hsuan, Park, Jin, Corbett, Brian F., Seibt, Frederik M., Beierlein, Michael, Chin, Jeannie (2021). Restoring activity in the thalamic reticular nucleus improves sleep architecture and reduces A beta accumulation in mice . Science Translational Medicine.

Jagirdar, Rohan, Chin, Jeannie (2019). Corticothalamic network dysfunction and Alzheimer's disease . Brain Research.

Jagirdar, Rohan, Seibt, Frederik M., Beierlein, Michael, Chin, Jeannie (2019). RESTORATION OF ACTIVITY IN THE THALAMIC RETICULAR NUCLEUS IMPROVES SLOW WAVE SLEEP AND REDUCES ABETAPLAQUE DEPOSITION IN ALZHEIMER'S DISEASE MICE . Sleep.

Jagirdar, Rohan, Drexel, Meinrad, Bukovac, Anneliese, Tasan, Ramon O., Sperk, Guenther (2016). Expression of class II histone deacetylases in two mouse models of temporal lobe epilepsy . Journal of Neurochemistry.

Jagirdar, Rohan, Drexel, Meinrad, Kirchmair, Elke, Tasan, Ramon O., Sperk, Guenther (2016). Rapid changes in expression of class I and IV histone deacetylases during epileptogenesis in mouse models of temporal lobe epilepsy (vol 273, pg 92, 2015) . Experimental Neurology.

Jagirdar, Rohan, Drexel, Meinrad, Kirchmair, Elke, Tasan, Ramon O., Sperk, Guenther (2015). Rapid changes in expression of class I and IV histone deacetylases during epileptogenesis in mouse models of temporal lobe epilepsy . Experimental Neurology.